| 颜坚,蔡玉莲,邓江涛,张涛.玻璃体腔注射雷珠单抗联合577 nm眼底激光治疗视网膜静脉阻塞继发黄斑水肿的临床疗效.[J].中南医学科学杂志.,2021,(6):717-720. |
| 玻璃体腔注射雷珠单抗联合577 nm眼底激光治疗视网膜静脉阻塞继发黄斑水肿的临床疗效 |
| Clinical efficacy of intravitreal injection of Lucentis combined with 577 nm fundus laser on macular edema secondary to retinal vein occlusion |
| 投稿时间：2021-01-14 修订日期：2021-03-09 |
| DOI：10.15972/j.cnki.43-1509/r.2021.06.025 |
| 中文关键词: 玻璃体腔 雷珠单抗 眼底激光 视网膜静脉阻塞 黄斑水肿 |
| 英文关键词:intravitreal Lucentis fundus laser retinal vein occlusion macular edema |
| 基金项目: |
|
| 摘要点击次数: 328 |
| 全文下载次数: 207 |
| 中文摘要: |
| 目的观察玻璃体腔注射雷珠单抗联合577 nm眼底激光治疗视网膜静脉阻塞继发黄斑水肿的临床疗效。方法选取视网膜静脉阻塞继发黄斑水肿患者82例(82眼),采用随机数字表法分为观察组(玻璃体腔注射雷珠单抗联合577 nm眼底激光治疗41例41眼)、对照组(577 nm眼底激光治疗41例41眼)。比较两组临床疗效,治疗前、治疗后3个月、治疗后6个月最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CRT),治疗前、治疗后6个月固视情况,统计两组患者6个月内复发情况、全身及眼部并发症发生情况。结果观察组治疗总有效率高于对照组(P＜0.05)；两组治疗后3个月、治疗后6个月BCVA较治疗前均有所改善(P＜0.05),两组治疗后3个月、治疗后6个月BCVA组间差异有统计学意义(P＜0.05)；治疗后3个月、治疗后6个月CRT较治疗前均显著降低(P＜0.05),观察组治疗后3个月、治疗后6个月CRT均显著低于对照组(P＜0.05)；观察组治疗后6个月固视情况较对照组改善(P＜0.05)。结论玻璃体腔注射雷珠单抗联合577 nm眼底激光治疗视网膜静脉阻塞继发黄斑水肿可有效缓解症状,提高视力,改善视功能,同时不良反应轻微,安全性高。 |
| 英文摘要: |
| To observe the clinical efficacy of intravitreal injection of Lucentis combined with 577 nm fundus laser in the treatment of macular edema secondary to retinal vein occlusion. MethodsEighty-two patients (82 eyes) with macular edema secondary to retinal vein occlusion were selected and divided into observation group (intravitreal injection of Lucentis combined with 577 nm fundus laser, 41 eyes and 41 eyes) and control group (577nm fundus laser treatment, 41 cases and 41 eyes) according to the random number table method. The clinical efficacy, as well as best corrected visual acuity (BCVA) and central retinal thickness (CRT) before treatment and at 3 months after treatment and at 6 months after treatment and fixation before treatment and at 6 months after treatment were compared between the two groups. The recurrence and occurrence of systemic and ocular complications within 6 months were counted in the two groups. ResultsThe total effective rate of treatment in observation group was significantly higher than that in control group (P＜0.05). The BCVA in observation group was improved at 3 months and 6 months after treatment compared with that before treatment (P＜0.05), and there was a statistically significant difference in the BCVA at 3 months and 6 months after treatment between the two groups (P＜0.05). CRT at 3 months and 6 months after treatment were significantly decreased compared with that before treatment (P＜0.05), and the CRT at 3 months and 6 months after treatment in observation group was significantly lower than that in control group (P＜0.05). The fixation index in observation group at 6 months after treatment was improved compared with that in control group (P＜0.05). ConclusionIntravitreal injection of Lucentis combined with 577 nm fundus laser for macular edema secondary to retinal vein occlusion can effectively relieve symptoms, improve vision, and promote visual function, and it has mild adverse reactions and high safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|